Your session is about to expire
← Back to Search
Dupilumab for Asthma (VIA Trial)
VIA Trial Summary
This trial is testing whether the drug dupilumab can help prevent people with mild to moderate asthma from having increased symptoms after being exposed to the common cold virus.
VIA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowVIA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.VIA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your blood eosinophil count is 150 or higher, or your FeNO level is 20 or higher.You have a positive methacholine test with a concentration of 16 milligrams per milliliter or less.I have had an asthma attack in the last 6 weeks.My asthma is managed with albuterol and possibly low to medium dose ICS, without anti-inflammatory meds for sinus issues.I have COPD or another serious lung condition.I use inhaled nasal sprays.I have been diagnosed with asthma for over 6 months.My asthma is mild and has been well controlled for the last 6 months.You have low levels of specific antibodies in your blood related to certain viruses.I have had an asthma attack that needed a doctor's visit or steroids in the last 3 years.I am using or willing to use effective birth control during and 4 months after the study.You can exhale a large amount of air in one second.I am between 18 and 40 years old.I have been hospitalized or visited the ER for severe asthma attacks.I haven't taken antiviral or immune therapies in the last 3 months.I have smoked for more than 10 years and over 10 pack-years.I have taken asthma biologic therapy, like dupilumab, in the last 3 months.I have not had a respiratory infection in the last 6 weeks.
- Group 1: Dupilumab
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is Dupilumab a reliable treatment for individuals with no adverse effects?
"The clinical data on Dupilumab reveals that it is approved for use, so this medication was given a 3 out of 3 safety rating."
What is the participant quantity for this scientific trial?
"Affirmative. According to what is posted on clinicaltrials.gov, this medical trial commenced looking for participants on May 1st 2022 and was most recently edited on the 16th of that same month. The research team aims to recruit 60 individuals from a single centre."
Who meets the criteria for enrollment in this medical research study?
"To be considered for admission, patients must possess asthma and lie between the ages of 18-40. This trial is currently seeking 60 participants."
Have any previous experiments employed Dupilumab for research?
"At present, there are forty-nine Dupilumab clinical trials with thirteen of them in the most advanced phase of research. These studies have been originating from Palo Alto, California while being conducted at 2602 sites across the country."
Are there any vacancies remaining in this clinical research?
"Affirmative. The clinicaltrials.gov website demonstrates that this medical trial was initially posted on May 1st 2022 and is actively recruiting for 60 patients at one site."
Is this the inaugural clinical trial of its kind?
"At this moment, there are 49 active Dupilumab trials being conducted in 436 cities and 43 countries. Sanofi's Phase 3 study of the drug began in 2015, enrolling 880 participants. From that point onwards, 54 trials have been successfully concluded."
Does the research team accept participants aged under eighty for this experiment?
"This trial is looking for volunteers aged 18 to 40 years old."
What afflictions are generally addressed by Dupilumab remedies?
"Dupilumab is primarily used to treat dermatitis, atopic and can also be an effective way of managing failure with corticosteroid therapy, eosinophil-related illnesses and asthma."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger